Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

Date publication

février 2016

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle , Pr WESTEEL Virginie

Tous les auteurs :
Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26598547

Résumé

HER2 mutations have been identified as oncogenic drivers in lung cancers and are found in 1-2% of lung adenocarcinomas. There is, to date, no standard of care for these patients. We thus aim to study the therapeutic outcomes of patients harboring HER2 mutations and establish the efficacy of various drug regimens.

Mots clés

Adenocarcinoma, drug therapy, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, therapeutic use, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Cohort Studies, Disease-Free Survival, Europe, Female, Humans, Lung Neoplasms, drug therapy, Male, Middle Aged, Molecular Targeted Therapy, methods, Quinazolines, therapeutic use, Quinolines, therapeutic use, Receptor Protein-Tyrosine Kinases, genetics, Receptor, Epidermal Growth Factor, genetics, Receptor, ErbB-2, genetics, Retrospective Studies, Trastuzumab, therapeutic use, Treatment Outcome

Référence

Ann. Oncol.. 2016 Feb;27(2):281-6